LABT
Lakewood-Amedex Biotherapeutics Inc. Common StockstockNASDAQ
Market OpenNov 5, 2026 1:00:09 PM EST
0.51USD+164.798%(+0.32)580,919,508
Pre-marketNov 5, 2026 9:29:30 AM EST
0.3899USD+102.440%(+0.1973)
Loading…
Loading…
1.28M
Previous Close
$0.19
Beta
-0.09
52-Week High
$98.20 2026-04-23
52-Week Low
$0.17 2026-11-02
SMA 50
$1.27
SMA 200
$7.07
Avg. Vol 10D
7.86M
Avg. Vol 30D
4.23M
Avg. Vol 90D
2.70M
Relative Vol
46.36
2.37M
283,275
11.95%
90,040
31.79%
1.00
45%/55%
51.96%
25.21%
212.3900%
20
26,374
218,302
Nov 12, 2026 (7d)
Jun 22, 2026 · 1-for-10 (reverse)
Nov 5, 2026
Oct 21, 2026
Oct 7, 2026
Oct 1, 2026
Sep 28, 2026
LABT: First Patient Dosed in Phase 2a Trial of Nu-3 for Infected Diabetic Foot Ulcers ·
Zacks Small Cap Research
LABT Performance
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 0.24 | 2026-10-29 | +126.84% | 4.629 |
| 1M | 0.85 | 2026-10-05 | -37.03% | 3.605 |
| 3M | 2.31 | 2026-08-05 | -76.70% | 1.820 |
| 6M | 31.00 | 2026-05-05 | -98.26% | 0.347 |
| 1Y | 86.50 | 2026-04-23 | -99.38% | -0.086 |
LABT Stock Summary
Lakewood-Amedex Biotherapeutics Inc. Common Stock (NASDAQ:LABT) stock price today is $0.54, and today's volume is 196,312,046. LABT is up 181.243% today. The 30 day average volume is 4.23M. LABT market cap is $1.28M with 2.37M shares outstanding.